Forfivo XL Shortage: What Providers and Prescribers Need to Know in 2026

If your patients with major depressive disorder are calling your office frustrated that their Forfivo XL prescription can't be filled, this guide is for you. The access challenges surrounding Forfivo XL (bupropion hydrochloride 450 mg extended-release) in 2026 are real and require proactive clinical management. This article covers the full picture: the commercial factors driving access barriers, how to navigate prior authorizations, what clinical alternatives to consider, and how to help patients maintain treatment continuity.

What Is the Current Forfivo XL Access Situation?

Forfivo XL is not on the FDA's or ASHP's official drug shortage list as of 2026. The drug is being manufactured and distributed by Almatica Pharma. However, patients are experiencing access problems driven by three commercial factors:

Formulary exclusions by major PBMs. Express Scripts placed Forfivo XL on its National Preferred Formulary Exclusion List in 2025, meaning millions of commercially insured patients affiliated with Express Scripts plans lose coverage. Your patients who use UnitedHealthcare, Cigna, Aetna, or other insurers that contract with Express Scripts may be affected.

Low routine pharmacy stocking. Due to a smaller patient population (Forfivo XL cannot initiate therapy), many pharmacies don't routinely stock it. Patients may face 3-7 day delays even after the prescription is sent.

High cash price. Retail cost ranges from $395-$566 for a 30-day supply without coverage. Even with GoodRx, the cost is approximately $132-$133/month — substantially more than generic bupropion XL alternatives costing under $20/month.

Why Patients Are Prescribed Forfivo XL: A Clinical Recap

Forfivo XL is the only commercially available single-tablet formulation of bupropion at the 450 mg dose. Per FDA labeling and clinical guidelines, it is appropriate for:

Patients who have been on 300 mg/day of another bupropion formulation for at least 2 weeks and require dose escalation to 450 mg/day for better efficacy.

Patients already established on 450 mg/day of another bupropion product who prefer the convenience and adherence benefit of a single tablet.

Patients who have demonstrated inadequate response at 300 mg and are being titrated to the maximum recommended daily dose.

Important prescribing reminder: Forfivo XL is contraindicated in patients with a seizure disorder, current or prior history of anorexia nervosa or bulimia, MAOI use within 14 days, and concurrent use of other bupropion-containing products. Seizure risk is dose-dependent — the 450 mg dose carries a higher seizure risk than lower doses.

Navigating Prior Authorization for Forfivo XL

For plans that don't outright exclude Forfivo XL but require prior authorization, your clinical documentation is key. A successful PA for Forfivo XL typically requires:

Documentation of prior trials and failure at lower doses of bupropion (e.g., 300 mg/day for ≥4-8 weeks with inadequate response).

Clinical rationale for requiring the single 450 mg tablet formulation specifically (e.g., polypharmacy burden, demonstrated non-adherence with multiple tablets).

MDD diagnosis confirmation with ICD-10 code (F32.x or F33.x).

Medical necessity letter explaining why a generic two-tablet regimen is not clinically appropriate for this patient.

For plans that fully exclude Forfivo XL (like those using Express Scripts' National Preferred Formulary), prior auth may not help unless the patient qualifies for a medical exception. In these cases, advise the patient on cash-pay options or clinical alternatives.

Clinical Alternatives When Forfivo XL Is Inaccessible

The most clinically equivalent alternative is generic bupropion hydrochloride extended-release in combination (300 mg XL + 150 mg XL once daily = 450 mg total). This delivers the same active ingredient, same total dose, and same pharmacokinetic profile. From a formulary perspective, generic bupropion XL is virtually always covered and costs under $20/month with discount programs.

For patients who have failed multiple antidepressants or who need a different mechanism, consider:

Aplenzin (bupropion HBr 522 mg): Bioequivalent to bupropion HCl 450 mg; some patients with inadequate HCl response show improvement on HBr. Manufacturer copay card can reduce cost to $0 for eligible patients.

Trintellix (vortioxetine 10-20 mg): Serotonin modulator with evidence for cognitive symptom improvement; may be useful for patients with prominent cognitive complaints.

SNRIs (duloxetine, venlafaxine XR): Both norepinephrine-active agents with broad formulary coverage; generics widely available at low cost.

Bridging Therapy to Prevent Treatment Gaps

Abrupt discontinuation of antidepressants is clinically inadvisable and may precipitate depressive relapse. If a patient cannot obtain Forfivo XL urgently, prescribe a bridge supply of generic bupropion XL 300 mg + 150 mg while the long-term access solution is arranged. This can typically be authorized quickly via telephone or electronic prescription.

Referring Patients to medfinder

For patients who want to stay on Forfivo XL while you work on a prior auth or coverage appeal, medfinder can help them locate a nearby pharmacy with Forfivo XL in stock. Providers can recommend medfinder.com as a pharmacy-finding service — patients submit their medication, dosage, and location, and medfinder calls pharmacies to identify which ones can fill the prescription. This helps bridge the gap while insurance coverage is resolved.

Summary: Provider Action Items for Forfivo XL Access Issues

Check the patient's insurance formulary before prescribing — particularly if they are on an Express Scripts-managed plan.

For PA-eligible plans: document prior bupropion trials, MDD diagnosis, and clinical rationale for single-tablet formulation.

Bridge with generic bupropion XL 300 mg + 150 mg while resolving coverage issues.

For cash-pay patients: advise manufacturer savings card, GoodRx, or consider switching to generic.

Refer patients to medfinder to locate pharmacies with Forfivo XL in stock.